Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Lmcg Investments LLC

Lmcg Investments LLC raised its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,404 shares of the medical research company’s stock after acquiring an additional 257 shares during the quarter. Lmcg Investments LLC’s holdings in Amgen were worth $9,749,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. Solidarity Wealth LLC acquired a new stake in Amgen in the fourth quarter valued at approximately $1,098,000. Crossmark Global Holdings Inc. boosted its position in shares of Amgen by 2.6% during the 4th quarter. Crossmark Global Holdings Inc. now owns 76,607 shares of the medical research company’s stock worth $19,967,000 after acquiring an additional 1,966 shares in the last quarter. Royal Fund Management LLC increased its holdings in shares of Amgen by 32.7% in the 4th quarter. Royal Fund Management LLC now owns 20,077 shares of the medical research company’s stock valued at $5,346,000 after acquiring an additional 4,942 shares during the last quarter. Mitchell & Pahl Private Wealth LLC raised its position in shares of Amgen by 13.0% during the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 5,879 shares of the medical research company’s stock worth $1,532,000 after acquiring an additional 676 shares in the last quarter. Finally, Ballentine Partners LLC lifted its position in shares of Amgen by 1.5% during the 4th quarter. Ballentine Partners LLC now owns 14,097 shares of the medical research company’s stock worth $3,674,000 after buying an additional 202 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 1.0 %

Shares of NASDAQ AMGN opened at $272.11 on Tuesday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm’s 50-day moving average is $273.95 and its two-hundred day moving average is $307.18. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a market capitalization of $146.27 billion, a PE ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGNGet Free Report) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.96 EPS. Equities analysts anticipate that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.50%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is presently 121.90%.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Barclays lifted their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Wells Fargo & Company decreased their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research report on Friday, January 10th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, UBS Group dropped their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $314.91.

Read Our Latest Report on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.